4921861 pharmaceutical compositions

1
xxii New Patents 4921856 4921864 DIHYDROPYRIDAZINONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS 4-PHENYL-4 (N-(PHENYL)AMIDO) PIPERIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND METHOD EMPLOYING SUCH COMPOUNDS Hdlmut Schickaneder, Peter Morsdorf, Volker Pfahlert, Heidrun Engler, Kurt H Ahrens, Eckental, Federal Republic Of Germany as- signed to Heumann Pharma GmbH & Company New dihydropryidazinone derivatives cor- responding to the following formula See Patent for Chemical Structure (I) and a process for their preparation and pharmaceutical preparations containing these compounds are described. These compounds are effective positively inotro- pic substances with an improved therapeutic profile. Linas V Kudzma, H Kenneth Spencer, Sherry A Severnak assigned to BOC Inc Compounds are disclosed of the formula See Pa- tent for Chemical Structure where R2 is unsub- stituted or substituted phenyl, R3 is lower alkyl, lower cycioalkyl or lower alkoxy lower alkyl, and L is selected from a wide variety of groups. This new class of compounds exhibit improved analgesic and anesthetic properties. 4921871 ENOLAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING INFLAMMATION 4921861 PHARMACEUTICAL COMPOSITIONS Jozsef Knoll, ne Simonyi Katalin Budai, ne Pol- dermann Edit Berenyi, Ildiko Miklya, Marton Fekete, Gabriella Zsilla, Berta Knoll, Attila Mandi, Lujza Petocz, Istvan Gyertyan, Istvan Gacsalyi, Budapest, Hungary assigned to BASF Aktiengesellschaft Mary Carethers, Wiaczeslaw Cetenko, David T Connor, Elizabeth Johnson, John S Kiely, Char- les Schwender, Jagadish C Sircar, Roderick Sorenson, Paul C Unangst, Robert F Bruns as- signed to Warner-Lambert Company The present invention relates to novel enolamide type compounds, pharmaceutical compositions, and methods of use thereof, useful in the treat- ment of diseases in which products of lipoxy- genase enzyme activity or the action of leukotrienes contribute to the pathological con- dition. The 3-amino-4-ethylthio-quinoline of the For- mula I See Patent for Chemical Structure (I) and pharmaceutically acceptable acid addition salts thereof possess useful therapeutical properties. They exhibit a potent and highly selective anx- iolytic and narcosis potentiating effect and are devoid of sedative and anti-convulsive effect. Consequently, the invention relates to pharma- ceutical compositions comprising the compound of Formula I or a salt thereof as active agent. The invention also relates to a new and improved process for the preparation of the compound of Formula I. 4921887 THIAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Masaaki Matsuo, Takashi Manabe, Shinj Shigenaga, Hiroshi Matsuda, Toyonaka, Japan assigned to Fujisawa Pharmaceutical Company Ltd

Upload: ngodan

Post on 05-Jan-2017

213 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: 4921861 Pharmaceutical compositions

xxii New Patents

4921856 4921864

DIHYDROPYRIDAZINONE D E R I V A T I V E S , A P R O C E S S F O R

T H E I R P R E P A R A T I O N A N D P H A R M A C E U T I C A L

P R E P A R A T I O N S C O N T A I N I N G T H E S E C O M P O U N D S

4 - P H E N Y L - 4 ( N - ( P H E N Y L ) A M I D O ) P I P E R I D I N E D E R I V A T I V E S A N D

P H A R M A C E U T I C A L C O M P O S I T I O N S A N D M E T H O D

E M P L O Y I N G S U C H C O M P O U N D S

Hdlmut Schickaneder, Peter Morsdorf, Volker Pfahlert, Heidrun Engler, Kurt H Ahrens, Eckental, Federal Republic Of Germany as- signed to Heumann Pharma GmbH & Company

New dihydropryidazinone derivatives cor- responding to the following formula See Patent for Chemical Structure (I) and a process for their preparation and pharmaceutical preparations containing these compounds are described. These compounds are effective positively inotro- pic substances with an improved therapeutic profile.

Linas V Kudzma, H Kenneth Spencer, Sherry A Severnak assigned to BOC Inc

Compounds are disclosed of the formula See Pa- tent for Chemical Structure where R2 is unsub- stituted or substituted phenyl, R3 is lower alkyl, lower cycioalkyl or lower alkoxy lower alkyl, and L is selected from a wide variety of groups. This new class of compounds exhibit improved analgesic and anesthetic properties.

4921871

E N O L A M I D E S , P H A R M A C E U T I C A L

C O M P O S I T I O N S A N D M E T H O D S OF U S E T H E R E O F F O R

T R E A T I N G I N F L A M M A T I O N

4921861

P H A R M A C E U T I C A L C O M P O S I T I O N S

Jozsef Knoll, ne Simonyi Katalin Budai, ne Pol- dermann Edit Berenyi, Ildiko Miklya, Marton Fekete, Gabriella Zsilla, Berta Knoll, Attila Mandi, Lujza Petocz, Istvan Gyertyan, Istvan Gacsalyi, Budapest, Hungary assigned to BASF Aktiengesellschaft

Mary Carethers, Wiaczeslaw Cetenko, David T Connor, Elizabeth Johnson, John S Kiely, Char- les Schwender, Jagadish C Sircar, Roderick Sorenson, Paul C Unangst, Robert F Bruns as- signed to Warner-Lambert Company

The present invention relates to novel enolamide type compounds, pharmaceutical compositions, and methods of use thereof, useful in the treat- ment of diseases in which products of lipoxy- genase enzyme activity or the action of leukotrienes contribute to the pathological con- dition.

The 3-amino-4-ethylthio-quinoline of the For- mula I See Patent for Chemical Structure (I) and pharmaceutically acceptable acid addition salts thereof possess useful therapeutical properties. They exhibit a potent and highly selective anx- iolytic and narcosis potentiating effect and are devoid of sedative and anti-convulsive effect. Consequently, the invention relates to pharma- ceutical compositions comprising the compound of Formula I or a salt thereof as active agent. The invention also relates to a new and improved process for the preparation of the compound of Formula I.

4921887

T H I A Z O L E C O M P O U N D S A N D P H A R M A C E U T I C A L

C O M P O S I T I O N C O M P R I S I N G T H E S A M E

Masaaki Matsuo, Takashi Manabe, Shinj Shigenaga, Hiroshi Matsuda, Toyonaka, Japan assigned to Fujisawa Pharmaceutical Company Ltd